Trials / Unknown
UnknownNCT00353964
Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery
A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Evolutec Group · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rEV131 | |
| DRUG | Prenisolone sodium phosphate 1.0% | |
| DRUG | rEV131 vehicle |
Timeline
- First posted
- 2006-07-19
- Last updated
- 2006-07-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00353964. Inclusion in this directory is not an endorsement.